FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AETERNA ZENTARIS INC. As filed with the Securities and Exchange Commission on February 15, 2024 Registration No. 333-___________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Canada 2 ...

Financial Performance - Revenues for the nine months ended September 30, 2023, increased to $4,377,000 from $3,155,000 for the same period in 2022, marking an increase of approximately 38.7%[6] - For the three months ended September 30, 2023, the Company recorded total revenue of $3, a significant decrease from $1,860 in the same period of 2022, representing a decline of 99.84%[17] - For the nine months ended September 30, 2023, total revenue was $4,377, compared to $3,155 for the same period in 2022, indicating an increase of 38.67%[17] - The Company recognized $1,658 (€1,540) in transaction price allocated to unsatisfied performance obligations related to the licensing agreement with Pharmanovia[18] Net Loss and Earnings Per Share - Net loss for the nine months ended September 30, 2023, was $10,917,000 compared to a net loss of $10,276,000 for the same period in 2022, indicating a loss increase of about 6.3%[6] - For the three months ended September 30, 2023, the net loss was $4,145,000, compared to a net loss of $3,420,000 for the same period in 2022, representing an increase of 21.2%[33] - The basic and diluted loss per share for the three months ended September 30, 2023, was $(0.85), compared to $(0.70) for the same period in 2022, reflecting a 21.4% increase[33] - For the nine months ended September 30, 2023, the net loss was $10,917,000, compared to $10,276,000 for the same period in 2022, an increase of 6.2%[33] - The basic and diluted loss per share for the nine months ended September 30, 2023, was $(2.25), compared to $(2.12) for the same period in 2022, indicating a 6.1% increase[33] Assets and Liabilities - As of September 30, 2023, total assets decreased to $42,486,000 from $56,026,000 as of December 31, 2022, representing a decline of approximately 24.2%[2] - Cash and cash equivalents decreased to $38,756,000 from $50,611,000, a reduction of about 23.5%[2] - Total current liabilities decreased to $4,228,000 from $7,044,000, a decrease of approximately 40.5%[2] - Shareholders' equity as of September 30, 2023, was $26,278,000, down from $35,776,000 as of December 31, 2022, reflecting a decrease of about 26.6%[2] - As of September 30, 2023, the total deferred revenue was $1,737, a decrease from $4,633 as of December 31, 2022, reflecting a reduction of 62.5%[21] - The Company’s employee future benefit obligations decreased from $21,750 at the beginning of the period to $20,343 by September 30, 2023, a reduction of 6.5%[24] - The Company’s net liability of the unfunded employee future benefit plans was $10,105 as of September 30, 2023, compared to $11,159 at the end of 2022, a decrease of 9.45%[24] Research and Development - Research and development expenses for the nine months ended September 30, 2023, increased to $9,692,000 from $8,081,000, an increase of approximately 20%[6] - The company has established a pre-clinical pipeline to address unmet medical needs across several indications, focusing on rare or orphan diseases[10] Business Development - The company is actively pursuing business development opportunities for the commercialization of its lead product, Macrilen, in various regions including North America and Asia[9] - The Company expects to supply a total of licensed product units to Pharmanovia based on current projections and anticipated market demand, which will significantly influence revenue recognition[18] Stock Options and Compensation - The compensation expense for stock options for the nine months ended September 30, 2023, was $66, down from $101 in the same period of 2022, a decrease of 34.65%[29] - The Company granted 14,000 stock options in 2023, compared to 2,000 in 2022, indicating a significant increase in stock options granted[27] Contractual Obligations - As of September 30, 2023, the company has significant expenditures contracted but not recognized as liabilities totaling $7,024,000, with $6,857,000 due within one year[36] - The company may have to pay up to $38,127,000 upon achieving certain sales volumes, regulatory, or other milestones related to specific products[36] Operating Segment - The company operates in a single operating segment, which is the biopharmaceutical segment[34]

Financial Performance - Revenues for the six months ended June 30, 2023, increased to $4,374,000 compared to $1,295,000 for the same period in 2022, marking a significant growth of 237.5%[7] - The net loss for the six months ended June 30, 2023, was $6,772,000, slightly lower than the net loss of $6,856,000 for the same period in 2022[7] - For the three months ended June 30, 2023, the Company reported total revenue of $2,246, compared to a loss of $222 in the same period of 2022, marking a significant increase[19] - License fees for the six months ended June 30, 2023, reached $1,554, a substantial increase from $226 in the same period of 2022[19] - The net loss for the three months ended June 30, 2023, was $2,518, compared to a net loss of $4,216 in the same period of 2022[34] Assets and Liabilities - As of June 30, 2023, total assets decreased to $46,483,000 from $56,026,000 as of December 31, 2022, representing a decline of approximately 17.0%[3] - Current assets decreased to $45,893,000, down 17.3% from $55,488,000 at the end of 2022, primarily due to a reduction in cash and cash equivalents[3] - Total liabilities decreased to $17,404,000 as of June 30, 2023, down 14.4% from $20,250,000 at the end of 2022[3] - Shareholders' equity decreased to $29,079,000 from $35,776,000, reflecting a decline of approximately 18.7%[3] - Cash and cash equivalents at the end of the period were $42,186,000, down from $50,611,000 at the beginning of the year, a decrease of 16.7%[9] Research and Development - Research and development expenses for the six months ended June 30, 2023, increased to $6,941,000, up 45.0% from $4,788,000 in the same period of 2022[7] Shareholder Information - The basic and diluted loss per share for the six months ended June 30, 2023, was $1.39, compared to $1.41 for the same period in 2022[7] - The basic and diluted loss per share for the six months ended June 30, 2023, was $1.39, slightly improved from $1.41 in the same period of 2022[34] - The Company’s share capital remained unchanged at 4,855,876 common shares as of June 30, 2023, with a total amount of $293,410[26] Commitments and Obligations - The Company’s employee future benefit obligations increased to $22,246 as of June 30, 2023, from $21,750 at the end of 2022[24] - As of June 30, 2023, the total significant expenditure contracted but not recognized as liabilities amounts to $7,774,000[37] - The company has commitments of $7,586,000 due within less than 1 year[37] - The company may have to pay up to $38,887,000 upon achieving certain sales volumes or regulatory milestones related to specific products[37] - Commitments for 1-3 years are recorded at $151,000[37] - Commitments for 4-5 years are recorded at $37,000[37] Business Development - The company is actively pursuing business development opportunities for the commercialization of its lead product, Macrilen, in various international markets[11] Stock Options - The Company granted 14,000 stock options on January 17, 2023, with a fair value at grant date of $2.99 per option[27] Deferred Revenue - Deferred revenue as of June 30, 2023, totaled $1,782, a decrease from $4,633 as of December 31, 2022[23] Revenue Recognition - The Company recognized revenue of $2,197 for services transferred over time for the three months ended June 30, 2023, compared to a loss of $283 in 2022[19] - The total units expected to be supplied to Pharmanovia under the licensing agreement is based on current projections and anticipated market demand, with a transaction price of $1,658 allocated to unsatisfied performance obligations[20]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ Registration Statement Pursuant to Section 12(b) or 12(g) of The Securities Exchange Act of 1934 OR ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 OR ☐ Shell Company Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Commis ...

Exhibit 99.1 Aeterna Zentaris Inc. Consolidated Financial Statements As of December 31, 2022 and 2021 and for the years ended December 31, 2022, 2021 and 2020 | Report of Independent Registered Public Accounting Firm (PCAOB ID:1263) | 2 | | --- | --- | | Report of Predecessor Independent Registered Public Accounting Firm (PCAOB ID:271) | 4 | | Consolidated Statements of Financial Position | 5 | | Consolidated Statements of Changes in Shareholders' Equity | 6 | | Consolidated Statements of Loss and Comprehen ...

[Condensed Interim Consolidated Financial Statements](index=1&type=section&id=Condensed%20Interim%20Consolidated%20Financial%20Statements) [Condensed Interim Consolidated Statements of Financial Position](index=2&type=section&id=Condensed%20Interim%20Consolidated%20Statements%20of%20Financial%20Position) As of March 31, 2022, total assets decreased to $76.3 million from $80.1 million, driven by reduced cash and current assets, while total liabilities also decreased to $23.2 million from $27.1 million, leading to stable shareholders' equity at $53.2 million Consolidated Statement of Financial Position (in thousands of US$) | Account | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Total Current Assets** | **67,097** | **70,820** | | Cash and cash equivalents | 63,596 | 65,300 | | **Total Assets** | **76,344** | **80,102** | | **Total Current Liabilities** | **5,666** | **7,766** | | **Total Liabilities** | **23,185** | **27,116** | | **Total Shareholders' Equity** | **53,159** | **52,986** | | **Total Liabilities and Shareholders' Equity** | **76,344** | **80,102** | [Condensed Interim Consolidated Statements of Changes in Shareholders' Equity](index=3&type=section&id=Condensed%20Interim%20Consolidated%20Statements%20of%20Changes%20in%20Shareholders%27%20Equity) For Q1 2022, total shareholders' equity increased slightly to $53.2 million, driven by comprehensive income offsetting a net loss, contrasting with Q1 2021's significant equity increase from financing activities Changes in Shareholders' Equity - Q1 2022 (in thousands of US$) | Description | Amount | | :--- | :--- | | Balance - January 1, 2022 | 52,986 | | Net loss | (2,640) | | Other comprehensive income | 2,786 | | Share-based compensation costs | 27 | | **Balance – March 31, 2022** | **53,159** | - In Q1 2021, the company raised significant capital, with **$30.98 million** from the issuance of common shares and **$19.99 million** from the exercise of warrants, which dramatically increased shareholders' equity[6](index=6&type=chunk)[66](index=66&type=chunk) [Condensed Interim Consolidated Statements of Comprehensive Income (Loss)](index=4&type=section&id=Condensed%20Interim%20Consolidated%20Statements%20of%20Comprehensive%20Income%20%28Loss%29) The company reported a net loss of $2.64 million for Q1 2022, up from $1.46 million in Q1 2021, driven by increased operating expenses, particularly research and development, despite a slight revenue decrease Q1 2022 vs Q1 2021 Performance (in thousands of US$) | Metric | Q1 2022 | Q1 2021 (Restated) | | :--- | :--- | :--- | | Total Revenues | 1,517 | 1,668 | | Research and development expenses | 2,390 | 1,458 | | Total operating expenses | 4,330 | 2,997 | | Loss from operations | (2,813) | (1,329) | | Net loss | (2,640) | (1,458) | | Comprehensive income (loss) | 146 | (29) | | Net loss per share (basic and diluted) | (0.02) | (0.02) | [Condensed Interim Consolidated Statements of Cash Flows](index=5&type=section&id=Condensed%20Interim%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2022, net cash used in operating activities increased to $1.46 million, while financing activities used $34,000, contrasting with Q1 2021's $50.9 million cash provided by financing, leading to a $1.7 million decrease in cash and equivalents Cash Flow Summary (in thousands of US$) | Activity | Q1 2022 | Q1 2021 (Restated) | | :--- | :--- | :--- | | Net cash used in operating activities | (1,461) | (1,045) | | Net cash (used in) provided by financing activities | (34) | 50,933 | | Net cash used in investing activities | (6) | (507) | | **Net change in cash and cash equivalents** | **(1,704)** | **49,100** | | **Cash and cash equivalents – End of period** | **63,596** | **73,371** | - Financing activities in Q1 2021 included **$34.2 million** from the issuance of common shares and **$19.99 million** from the exercise of warrants, which were absent in Q1 2022[11](index=11&type=chunk)[71](index=71&type=chunk) [Notes to Condensed Interim Consolidated Financial Statements](index=6&type=section&id=Notes%20to%20Condensed%20Interim%20Consolidated%20Financial%20Statements) [Note 1: Business Overview](index=6&type=section&id=1.%20Business%20overview) This note details the company's biopharmaceutical business, IFRS basis of financial statement preparation, and the impact of external factors like COVID-19 and the Russia/Ukraine conflict, which delayed the DETECT-trial into 2023 and necessitated restatement of prior period figures [Summary of Business, Basis of Presentation, and Government Assistance](index=6&type=section&id=Summary%20of%20business%2C%20Basis%20of%20presentation%2C%20and%20Government%20assistance) Aeterna Zentaris is a biopharmaceutical company focused on therapeutics and diagnostics, with Macrilen™ as its lead product for AGHD, and is developing a pre-clinical pipeline for rare indications, with financial statements prepared under IFRS - The company's lead product is **Macrilen™ (macimorelin)**, an oral test for Adult Growth Hormone Deficiency (AGHD), marketed in the US by Novo Nordisk and in Europe/UK by Consilient Healthcare[13](index=13&type=chunk)[73](index=73&type=chunk) - The company is also focused on developing a pre-clinical pipeline for rare or orphan indications, with potential for pediatric use[13](index=13&type=chunk)[73](index=73&type=chunk) - Financial statements are prepared in accordance with **IFRS**, and the company has adopted **IAS 20** for accounting for government grants[14](index=14&type=chunk)[74](index=74&type=chunk) [COVID-19 & Russia and Ukraine Conflict](index=7&type=section&id=COVID-19%20%26%20Russia%20and%20Ukraine%20conflict) The COVID-19 pandemic and Russia/Ukraine conflict have delayed the DETECT-trial's recruitment into 2023, leading to a **$1.2 million** reclassification of deferred revenue from current to long-term - The **DETECT-trial** has experienced delays in site initiation and patient enrollment due to the COVID-19 pandemic and the Russia/Ukraine conflict[16](index=16&type=chunk)[76](index=76&type=chunk) - As a result of the delays, the recruitment for the DETECT-trial is now expected to continue into **2023**, revised from the previous estimate of late 2022[16](index=16&type=chunk)[76](index=76&type=chunk) - Due to the revised timeline, **$1.2 million** of deferred revenue has been reclassified from current to long-term as of March 31, 2022[16](index=16&type=chunk)[76](index=76&type=chunk) [Restatement of Comparative Period Figures](index=7&type=section&id=Restatement%20of%20comparative%20period%20figures) The company restated its 2021 interim financial statements due to a re-evaluation of the DETECT-trial arrangement with Novo Nordisk, reclassifying charges from R&D expenses to development services revenue under IFRS 15 - The company restated its condensed consolidated interim financial statements for the three, six, and nine-month periods of **2021**[18](index=18&type=chunk)[78](index=78&type=chunk) - The restatement stemmed from a re-evaluation of the **DETECT-trial** activities with Novo Nordisk, which were determined to no longer be a joint operation under **IFRS 11**[18](index=18&type=chunk)[78](index=78&type=chunk) - Consequently, charges to Novo were reclassified from research and development expenses to development services revenue, and related license fees and deferred revenues were also adjusted[18](index=18&type=chunk)[78](index=78&type=chunk) [Note 2: Critical Accounting Estimates and Judgements](index=8&type=section&id=2.%20Critical%20accounting%20estimates%20and%20judgements) Management's preparation of financial statements requires significant judgments, estimates, and assumptions, which remain consistent with those applied in the annual financial statements for the year ended December 31, 2021 - Management is required to make judgments, estimates, and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses[21](index=21&type=chunk)[81](index=81&type=chunk) - The critical accounting estimates and judgments applied in these interim statements are the same as those applied in the annual financial statements for the year ended **December 31, 2021**[22](index=22&type=chunk)[82](index=82&type=chunk) [Note 3: License and Supply Arrangements](index=8&type=section&id=3.%20License%20and%20supply%20arrangements) The company generates revenue from Macrilen™ license and supply agreements with key partners like Novo Nordisk and Consilient Health, with total deferred revenue at **$5.37 million** as of March 31, 2022, down from **$6.31 million** at year-end 2021 - The company has key licensing agreements for **Macrilen™** with Novo Nordisk (U.S./Canada), Consilient Health (Europe/UK), MegaPharm (Israel), and NK Meditech (Korea)[23](index=23&type=chunk)[24](index=24&type=chunk)[25](index=25&type=chunk) Deferred Revenue from License Agreements (in thousands of US$) | Agreement | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | Novo Amendment | 3,908 | 4,814 | | CH License Agreement | 1,324 | 1,358 | | NK License Agreement | 133 | 136 | | **Total** | **5,365** | **6,308** | [Note 4: Trade and Other Receivables](index=10&type=section&id=4.%20Trade%20and%20other%20receivables) Trade and other receivables decreased to **$693,000** as of March 31, 2022, from **$1.31 million** at year-end 2021, including a new **$146,000** grant receivable for pre-clinical programs Trade and Other Receivables Breakdown (in thousands of US$) | Item | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | Trade accounts receivable (net) | 302 | 877 | | Value-added tax | 193 | 372 | | Grant receivable | 146 | — | | Other | 52 | 65 | | **Total** | **693** | **1,314** | - In March 2022, the company was awarded a monetary subsidy of **$146,000** under a German tax incentive act for R&D on a SARS-CoV-2 vaccine and a treatment for neuromyelitis optica[29](index=29&type=chunk)[89](index=89&type=chunk) [Note 5: Prepaid Expenses and Other Current Assets](index=10&type=section&id=5.%20Prepaid%20expenses%20and%20other%20current%20assets) Prepaid expenses and other current assets decreased to **$1.05 million** as of March 31, 2022, from **$1.77 million** at year-end 2021, primarily due to reductions in prepaid research and development and prepaid insurance Prepaid Expenses Breakdown (in thousands of US$) | Item | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | Prepaid insurance | — | 421 | | Prepaid research and development | 907 | 1,329 | | Other | 143 | 22 | | **Total** | **1,050** | **1,772** | [Note 6: Payables and Accrued Liabilities](index=10&type=section&id=6.%20Payables%20and%20accrued%20liabilities) Payables and accrued liabilities slightly increased to **$2.80 million** as of March 31, 2022, from **$2.67 million** at year-end 2021, primarily comprising trade accounts payable, accrued R&D costs, and salaries Payables and Accrued Liabilities Breakdown (in thousands of US$) | Item | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | Trade accounts payable | 1,022 | 934 | | Salaries, employment taxes and benefits | 517 | 531 | | Accrued research and development costs | 695 | 596 | | Other accrued liabilities | 561 | 611 | | **Total** | **2,795** | **2,672** | [Note 7: Employee Future Benefits](index=11&type=section&id=7.%20Employee%20future%20benefits) The net liability for employee future benefits decreased to **$14.39 million** as of March 31, 2022, from **$17.49 million** at year-end 2021, primarily due to a **$3.19 million** actuarial gain from an increased discount rate - The net liability for employee future benefits decreased from **$17.49 million** at Dec 31, 2021 to **$14.39 million** at March 31, 2022[34](index=34&type=chunk)[94](index=94&type=chunk) - The reduction was largely due to an actuarial gain of **$3.19 million** arising from changes in financial assumptions, specifically an increase in the discount rate from **1.1%** to **1.7%**[34](index=34&type=chunk)[94](index=94&type=chunk) [Note 8: Share Capital, Warrants and Other Capital](index=12&type=section&id=8.%20Share%20capital%2C%20warrants%20and%20other%20capital) This note details the company's capital structure, highlighting **$34.2 million** raised from a public offering and **$20.0 million** from warrant exercises in Q1 2021, with **1,136,368** stock options and **423,000** DSUs outstanding as of March 31, 2022 - In February 2021, the company completed an underwritten public offering, raising aggregate gross proceeds of **$34.2 million**[38](index=38&type=chunk)[39](index=39&type=chunk)[99](index=99&type=chunk) - During the three months ended March 31, 2021, the exercise of **34,888,965** warrants generated aggregate proceeds of **$19.99 million**[41](index=41&type=chunk)[42](index=42&type=chunk)[101](index=101&type=chunk) - As of March 31, 2022, there were **1,136,368** stock options and **423,000** DSUs outstanding, with **50,000** new stock options granted during the quarter[43](index=43&type=chunk)[103](index=103&type=chunk) [Note 9: Operating Expenses](index=14&type=section&id=9.%20Operating%20expenses) Total operating expenses for Q1 2022 significantly increased to **$4.33 million** from **$3.00 million** in Q1 2021, primarily driven by higher research and development costs and increased employee benefits across R&D and G&A functions Operating Expenses Breakdown (in thousands of US$) | Expense Category | Q1 2022 | Q1 2021 | | :--- | :--- | :--- | | R&D - Employee benefits | 406 | 289 | | R&D - Professional services | 1,975 | 1,147 | | R&D - Government grant | (146) | — | | G&A - Employee benefits | 511 | 351 | | **Total Operating Expenses** | **4,330** | **2,997** | [Note 10: Supplemental Disclosure of Cash Flow Information](index=16&type=section&id=10.%20Supplemental%20disclosure%20of%20cash%20flow%20information) This note details changes in operating assets and liabilities affecting cash flow, showing a net positive change of **$1.13 million** for Q1 2022, mainly from decreases in trade receivables and prepaid expenses Changes in Operating Assets and Liabilities (in thousands of US$) | Item | Q1 2022 | Q1 2021 | | :--- | :--- | :--- | | Trade and other receivables | 474 | 650 | | Inventory | (206) | (40) | | Prepaid expenses and other current assets | 711 | (93) | | Payables and accrued liabilities | 159 | 115 | | Deferred revenues | 8 | 1,227 | | **Total** | **1,126** | **1,647** | [Note 11: Segment Information](index=16&type=section&id=11.%20Segment%20information) The company operates solely within the biopharmaceutical segment - The Company operates in a single operating segment, the biopharmaceutical segment[53](index=53&type=chunk)[113](index=113&type=chunk) [Note 12: Net Loss Per Share](index=16&type=section&id=12.%20Net%20loss%20per%20share) Net loss per share remained stable at **($0.02)** for Q1 2022, despite an increase in weighted average shares outstanding to **121.4 million**, with all stock options and warrants excluded from diluted EPS due to the net loss Net Loss Per Share Calculation (in thousands of US$) | Metric | Q1 2022 | Q1 2021 | | :--- | :--- | :--- | | Net loss (in thousands of US$) | (2,640) | (1,458) | | Basic weighted average shares | 121,397,007 | 95,444,990 | | Diluted weighted average shares | 121,397,007 | 95,444,990 | | **Net loss per share (basic & diluted)** | **(0.02)** | **(0.02)** | - In periods with reported net losses, all stock options and warrants are deemed anti-dilutive and are excluded from the calculation of diluted net loss per share[56](index=56&type=chunk)[116](index=116&type=chunk) [Note 13: Commitments](index=17&type=section&id=13.%20Commitments) The company has total contractual commitments of **$3.84 million**, with **$2.57 million** due within one year, and potential future milestone payments of up to **$41.07 million** for R&D and revenue, with uncertain timing Contractual Commitments (in thousands of US$) | Period | Service and manufacturing | R&D contracts | TOTAL | | :--- | :--- | :--- | :--- | | Less than 1 year | 518 | 2,056 | 2,574 | | 1 - 3 years | 638 | 630 | 1,268 | | 4 - 5 years | 1 | — | 1 | | **Total** | **1,157** | **2,686** | **3,843** | - The company has potential future milestone payments of up to **$8.76 million** for R&D and **$32.31 million** for revenue, totaling **$41.07 million**[59](index=59&type=chunk)[119](index=119&type=chunk) - The timing of milestone payments is not risk-adjusted and is based on the company's best estimate, acknowledging that pharmaceutical development is a complex and risky process[59](index=59&type=chunk)[119](index=119&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ Registration Statement Pursuant to Section 12(b) or 12(g) of The Securities Exchange Act of 1934 OR ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 OR ☐ Shell Company Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Commis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ Shell Company Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Commission file number 0-30752 Washington, D.C. 20549 FORM 20-F ☐ Registration Statement Pursuant to Section 12(b) or 12(g) of The Securities Exchange Act of 1934 OR ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the fiscal year ended December 31, 2019 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities ...